title: Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
abstract: OBJECTIVE
  A synthetic analogue of calcitriol, 22-oxacalcitriol (OCT), strongly suppresses parathyroid hormone (PTH) secretion. This study investigated the influence of OCT on PTH secretion and bone metabolism in 12 hemodialysis patients with secondary hyperparathyroidism.
  
  
  METHODS
  OCT was intravenously injected after every hemodialysis session (three times weekly) for 22 weeks. The levels of the following parameters were measured: intact PTH, whole PTH, whole PTH/7-84 PTH ratio, adjusted calcium, phosphorus, alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BAP), intact osteocalcin (OC), type I collagen carboxyterminal propeptide, tartrate-resistant acid phosphatase (TRAP), cross-linked C-terminal telopeptides of type I collagen, and interleukin-6.
  
  
  METHODS
  The subjects were 12 hemodialysis patients (8 men and 4 women) with an intact PTH level of more than 460 pg/ml, a normal serum calcium level, and a serum phosphorus of less than 7 mg/dl.
  
  
  RESULTS
  The levels of intact PTH, whole PTH, whole PTH/7-84 PTH ratio, ALP, BAP, OC, and TRAP were significantly decreased after OCT administration, while adjusted calcium was significantly increased. Serum phosphorus and the other parameters showed no significant changes.
  
  
  CONCLUSIONS
  OCT effectively suppressed the PTH level and bone metabolism parameters in hemodialysis patients with secondary hyperparathyroidism.
authors: Department of Internal Medicine, Harada Hospital, Hiroshima.
authors: Shigehiro
authors: S
authors: Doi
authors: Noriaki
authors: N
authors: Yorioka
authors: Koji
authors: K
authors: Usui
authors: Kenichiro
authors: K
authors: Shigemoto
authors: Satoru
authors: S
authors: Harada
mesh_terms: D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000378:metabolism; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002120:Calcium Channel Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D006435:Renal Dialysis
chemical_list: D002120:Calcium Channel Agonists; D010281:Parathyroid Hormone; D002117:Calcitriol; C051883:maxacalcitol